Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

January 4, 2019

Calquence Shows Durable Responses in Untreated CLL/SLL Patients in Phase 1/2 Trial

News

Calquence (acalabrutinib), given as a first-line treatment to patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), showed an acceptable safety profile and reduced tumor burden in 97 percent of patients in a Phase ... Read more

January 2, 2019

Immune Checkpoint Inhibitors Make Lymphoma Respond Better to Future Treatment, Studies Suggest

News

Patients with both Hodgkin’s and non-Hodgkin’s lymphoma who receive immune checkpoint inhibitors as their second-line or later treatment might respond better to their subsequent therapy, even if they failed to ... Read more